These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 4719916)

  • 41. [Hormonally induced changes of the portio caused by ovulation inhibitors].
    Guhr O
    Munch Med Wochenschr; 1972 Apr; 114(16):766-8. PubMed ID: 5067884
    [No Abstract]   [Full Text] [Related]  

  • 42. The use of Depo-Provera injections on a 6-monthly basis.
    Karstadt B
    S Afr Med J; 1976 Nov; 50(47):1887. PubMed ID: 1006452
    [No Abstract]   [Full Text] [Related]  

  • 43. [Carcinoma in situ and cervical carcinoma during the use of oral contraceptives].
    Wunder G
    Fortschr Med; 1973 Sep; 91(27):1082-4. PubMed ID: 4746761
    [No Abstract]   [Full Text] [Related]  

  • 44. Depo-Provera: costs eat up clinic contraceptive budgets.
    Contracept Technol Update; 1999 Jan; 20(1):1-3. PubMed ID: 12349019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Medicolegal issues surrounding Depo-Provera easily overcome.
    Contracept Technol Update; 1992 Jan; 13(1):16, 18. PubMed ID: 12343460
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cervical carcinoma in situ associated with azathioprine therapy. A case report and literature review.
    Balachandran I; Galagan KS
    Acta Cytol; 1984; 28(6):699-702. PubMed ID: 6391055
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Changes in the cervix uteri during corticosteroid administration].
    Guhr O
    Munch Med Wochenschr; 1973 Jun; 115(22):1020-2. PubMed ID: 4740863
    [No Abstract]   [Full Text] [Related]  

  • 48. Depo-Provera update.
    PIACT Prod News; 1982 Dec; 4(3):1, 4. PubMed ID: 12264595
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ask the experts: progestin-only contraceptives.
    Hatcher RA; Schnare S
    Contracept Technol Update; 1993 Jul; 14(7):114-5. PubMed ID: 12286999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What is breast cancer risk with Depo-Provera?
    Contracept Technol Update; 1992 Jan; 13(1):15-6. PubMed ID: 12343459
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Injectable medroxyprogesterone.
    Rosenfield AG
    Drug Ther (NY); 1975 Jul; 5():139. PubMed ID: 12229496
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Experience with contraceptive effect of Depo-Provera, 300mg and 450mg, administered in 6-month intervals].
    Havránek F; Tichý M; Divila F; Hejda V
    Cesk Gynekol; 1972 Mar; 37(2):95-6. PubMed ID: 5023983
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Modifications of various aspects of the cervical factor by using delayed action medroxyprogesterone. Preliminary report].
    Rueda González R
    Rev Colomb Obstet Ginecol; 1969; 20(1):31-4. PubMed ID: 5408432
    [No Abstract]   [Full Text] [Related]  

  • 55. Response to contraception.
    Roland M
    Major Probl Obstet Gynecol; 1973; 5():1-162. PubMed ID: 4781770
    [No Abstract]   [Full Text] [Related]  

  • 56. Relationship of oral contraceptives to cervical carcinogenesis.
    Thomas DB
    Obstet Gynecol; 1972 Oct; 40(4):508-18. PubMed ID: 5073446
    [No Abstract]   [Full Text] [Related]  

  • 57. Depo-provera (medroxyprogesterone acetate) as a female contraceptive agent.
    Soichet S
    Int J Fertil; 1969; 14(1):33-8. PubMed ID: 5766924
    [No Abstract]   [Full Text] [Related]  

  • 58. Prescribing tips for Depo-Provera.
    Contracept Technol Update; 1992 Jan; 13(1):4. PubMed ID: 12343462
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Depo-Provera: IPPF states the facts.
    IPPF News; 1978; 3(5):1. PubMed ID: 12260347
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera.
    Jain J; Dutton C; Nicosia A; Wajszczuk C; Bode FR; Mishell DR
    Contraception; 2004 Jul; 70(1):11-8. PubMed ID: 15208047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.